The biotech company said in its first quarter 2020 earnings that it would complete the submission of its Food and Drug Administration filing for aducanumab in the third quarter. An analyst wrote that it means the agency wouldn’t likely complete its review until after the presidential election.

LEAVE A REPLY

Please enter your comment!
Please enter your name here